Expert Highlights Assay to Determine Patients With Lung, Gastrointestinal Cancers to Receive Pembrolizumab
The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.
Source: OncLive